Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for fertility outcomes in infertile patients with adenomyosis undergoing IVF
IRCT20260209068816N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cabergoline in adenomyosis and infertility (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Implantation rate, Biochemical pregnancy rate and 2 more. Started Apr 2026; status: completed.
02
Drugs
cabergoline
03
Conditions
adenomyosisinfertility
Beyond the preview
Go deeper on IRCT20260209068816N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260209068816N1.